Cover Image
市場調查報告書

便秘:開發平台分析

Constipation - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192536
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
Back to Top
便秘:開發平台分析 Constipation - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 121 Pages
簡介

便秘,在排便困難或頻率少的情況發生。便秘的症狀有腹部的膨脹或腹痛,疼痛及嘔吐等。原因包含有飲食障礙、大腸躁鬱症、甲狀腺機能低下症、便秘藥過量使用、過勞、腸肌肉的衰弱、緊張狀態、水分的攝取不足、飲食的纖維不足等。治療有便秘藥的使用與恰當的生活方式。

本報告以全球便秘治療藥的開發平台為主題,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

便秘概要

治療藥的開發

  • 便秘開發中產品:概要
  • 便秘開發中產品:比較分析

便秘:正在開發的治療藥 - 各企業

便秘:正在開發的治療藥 - 各大學、研究機關

便秘:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

便秘:開發中的產品 - 各企業

便秘:開發中的產品 - 各大學、研究機關

便秘:開發治療藥的企業

  • AlbireoPharma
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Braintree Laboratories, Inc.
  • CJ HealthCare Corp.
  • 第一三共
  • Ironwood Pharmaceuticals, Inc.
  • Kissei藥品工業
  • NGM Biopharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Rhythm Pharmaceuticals, Inc.
  • 三和化學研究所
  • Shire Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.
  • 大日本住友製藥
  • Synergy Pharmaceuticals, Inc.
  • Synthetic Biologics, Inc.
  • Yuhan Corporation

便秘:治療藥的評估

  • 單劑治療藥
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ASP-7663
    • 產品概要
    • 作用機制
    • R&D的進展
  • BLI-400
  • DA-6886
  • DS-3801
  • DSP-6952
  • elobixibat
  • KWA-0711
  • linaclotide
  • lubiprostone
  • NGM-282
  • plecanatide
  • prucalopride succinate
  • relamorelin
  • relenopride hydrochloride
  • RQ-00000010
  • SK-1202
  • 便秘、消化不良治療用5-HT1受體活性小分子
  • 慢性便秘、大腸躁鬱症治療用 IBAT 抑制劑
  • SYN-010
  • tenapanor hydrochloride
  • Transilon
  • YH-12852

最新的開發平台趨勢

暫停中的計劃

產品開發里程碑

  • 注目新聞、新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8299IDB

Summary

Global Markets Direct's, 'Constipation - Pipeline Review, H2 2016', provides an overview of the Constipation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Constipation
  • The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects
  • The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Constipation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Constipation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Constipation Overview
  • Therapeutics Development
    • Pipeline Products for Constipation - Overview
    • Pipeline Products for Constipation - Comparative Analysis
  • Constipation - Therapeutics under Development by Companies
  • Constipation - Therapeutics under Investigation by Universities/Institutes
  • Constipation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Constipation - Products under Development by Companies
  • Constipation - Products under Investigation by Universities/Institutes
  • Constipation - Companies Involved in Therapeutics Development
    • AlbireoPharma
    • Ardelyx, Inc.
    • Astellas Pharma Inc.
    • Braintree Laboratories, Inc.
    • CJ HealthCare Corp.
    • EA Pharma Co Ltd
    • Ironwood Pharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Motus Therapeutics Inc
    • NGM Biopharmaceuticals, Inc.
    • RaQualia Pharma Inc.
    • Sanwa Kagaku Kenkyusho Co., Ltd.
    • Shire Plc
    • SK Biopharmaceuticals Co., Ltd.
    • Sucampo Pharmaceuticals, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Synergy Pharmaceuticals, Inc.
    • Synthetic Biologics, Inc.
    • Torrent Pharmaceuticals Limited
    • Yuhan Corporation
  • Constipation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 5-BIOP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AJG-555 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7663 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-14199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-6886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-6952 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elobixibat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KWA-0711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linaclotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lovastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lubiprostone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plecanatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relamorelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relenopride hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenapanor hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Transilon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-12852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Constipation - Dormant Projects
  • Constipation - Product Development Milestones
    • Featured News & Press Releases
      • Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
      • May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
      • May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
      • May 22, 2016: Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
      • May 21, 2016: Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
      • May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
      • May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
      • May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
      • May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
      • Apr 19, 2016: Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation
      • Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide)
      • Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
      • Jan 29, 2016: Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation
      • Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
      • Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Constipation, H2 2016
  • Number of Products under Development for Constipation - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Constipation - Pipeline by AlbireoPharma, H2 2016
  • Constipation - Pipeline by Ardelyx, Inc., H2 2016
  • Constipation - Pipeline by Astellas Pharma Inc., H2 2016
  • Constipation - Pipeline by Braintree Laboratories, Inc., H2 2016
  • Constipation - Pipeline by CJ HealthCare Corp., H2 2016
  • Constipation - Pipeline by EA Pharma Co Ltd, H2 2016
  • Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Constipation - Pipeline by Motus Therapeutics Inc, H2 2016
  • Constipation - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
  • Constipation - Pipeline by RaQualia Pharma Inc., H2 2016
  • Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
  • Constipation - Pipeline by Shire Plc, H2 2016
  • Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016
  • Constipation - Pipeline by Synthetic Biologics, Inc., H2 2016
  • Constipation - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
  • Constipation - Pipeline by Yuhan Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Constipation - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Constipation, H2 2016
  • Number of Products under Development for Constipation - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top